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Severedevelopmentalandreproductiv disorders in wildanimalshav beenlinkedtohighexpose
to persistent environmenta chemicals with hormonal cty. These adverse dects ofenviron-
mental etogens haveraisedconsiderable concern andhavereceiv sg attention.Although
numerous chemicals with thecapacitytointerferewiththeestrogenroceptor (ER) have been iden-
tified, information ontheirmolecularmechanismofactionandtheirrelativepotecyisratherlim-
ited. For the endometrium, the ladc ofinformation is due to the lack ofa suitable expemeta
model.Wein tedthe functions ofphy to in anenometria-derivedmodel, RUCA-I
rat endometrial d oma cel. The ceis were culured on areconstituted basement men-
brane toprewetheirfunctional diferentiation andestrogenreposveesWeassesedtherela-
tive binding affinity to the esto receptor ofthe sdectedphyteogens coumestoL geistein,
daidzein, and the putative phytoestrogen mangostin compared to estradiol by a competitive
Scatchard analysis. The followingafnity nkingwasmeasurec 171etradiol >>> coumestrol >
genistein> daidzein »>mango>. Inaddition, wein iad theopacity ofthesecompounds
to promote theinasedproduction ofcomplement C3, awell-kmown estadiol-rulated proen
ofthe rat endometrium. All substances tested increased the production ofcomplement C3,
although diferent concentratons were esy to achieve equivalent levels of induction com-
pared to estradiol. Mechnisically we were able to demon te that the increase ofcomplement
C3 prduction was mediated bypmai inas its steady-state.mRNAlevel. Thesefindings
indicate that RUCA-I cells repre a sensitive model system to elucidate reaivpotenes and
funcieonsof I estogens inanendometrium-deriedmodel.Key worxbindingaffini-
ty, comp estrogen ptr , racellular m phytmtroge. Environ
HeakbPerpea106:581-586 (1998). [Online 12August 1998]
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Accumulated evidence of the past 30 years
shows that humans and animals are exposed
to a variety of persistent environmental
xenoestrogens. These xenoestrogens have the
potential to affect the endocrine system and
cause developmental, endocrine, and onco-
logical disorders. Potential effects ofenviron-
mental estrogens on human health are
intensely debated with regard to declining
sperm quantity and quality in men (1-3) and
as a cause ofincreased rates ofbreast cancer
(4,5). Finally, there is dear evidence that off-
spring exposed in utero to diethylstilbestrol
are at an increased risk for the development
of reproductive tract abnormalities and rare
vaginal dear-cell adenocarcinomas (6,). The
possible pathways for xenoestrogens to inter-
fere with the endocrine system are manifold,
and involve inhibition of biosynthesis of
steroids and agonistic or antagonistic effects
associatedwithbinding to the estrogen recep-
tor (ER) as well as modifying bound-to-free
estradiol ratios. Endocrine disruptors can also
bind to a nonsteroidal receptor like the aryl
hydrocarbon receptor and exert estrogenic
and antiestrogenic properties. Others act as
estrogens apparently without mediation of
thereceptor.
Exposure to estrogenic industrial chemi-
cals may cause adverse endocrine effects,
whereas exposure to phytoestrogens such as
genistein, daidzein, and coumestrol may
induce beneficial effects. Many clinical and
epidemiologic studies describe a positive
correlation between a phytoestrogen-rich
diet and decreased risk for the develop-
ment of hormone-dependent cancers such
as prostate and breast cancer (8). Most
phytoestrogens bind to the estrogen recep-
tor with a lower affinity than 17p-estradiol
(E2) (9) and are weakly estrogenic (10).
The competition of these weak estrogens
with E2 for nudear binding might explain
antiestrogenic features of these substances
in vivo mainly observed regarding infertili-
ty and uterine wet weight (11,12). But to
date, no conclusive evidence exists that
phytoestrogens act as antiestrogens. The
molecular basis of the protective effects of
phytoestrogens remains unclear. To
increase ourknowledge about environmen-
tal estrogens, additional tissue-specific
model systems are required to aid in their
identification, assess their potency, and
elucidate their mechanisms of action.
Thus, it is important to have tissue-specific
model systems representing various
endocrine-responsive targets (e.g., breast as
well as endometrium).
To obtain a more comprehensive pic-
ture of the effects of phytoestrogens in
endometrial adenocarcinoma cells, we used
multiparameter analyses to assess the rela-
tive potency of the phytoestrogens coume-
strol, genistein, daidzein, and mangostin.
The binding affinity of the tested compo-
nents to the ER and effects on formation
and secretion of complement C3 served as
parameters. The level of hormonal regula-
tion of gene expression was assessed by
Northern blot analyses. For all experiments
we used the rat endometrial adenocarcino-
ma cell line RUCA-I, recendyestablished in
our laboratory. This cell line contains a rel-
ative high ER level (13). Cultivation of
these cells on a reconstituted basement
membrane in the presence of serum-free
defined medium induced hormone respon-
siveness as well as morphological differenti-
ation (14,15). The study presented here
demonstrates that this cell line can be a
valuable model system to investigate the
effects of phytoestrogens on endometrial
adenocarcinoma cells.
Materials and Methods
Hormones. The followingcontrol substances
were used for the treatment of RUCA-I
cells: E2 (10-710-i8 M, 99% purity; Sigma,
Deisenhofen, Germany) and the pure antag-
onist ICI 164384 (5 x 10-7-5 x 10-8 M,
research grade purity; kindly provided by
A.E. Wakeling, Zeneca Chemicals,
Macclesfield, UK) aswell as tamoxifen (106
M, >99% purity, Sigma), which has partial
agonistic and/or antagonistic properties.
The following phytoestrogens were used as
test substances: coumestrol (10A-i10-8 M,
95% purity; Fluka, Deisenhofen, Germany)
genistein (10-6_10-9 M, 98% purity;
Sigma), daidzein (10-6_10-9 M, purity
determined by thin layer chomatography;
Roth, Karlsruhe, Germany), and the puta-
tive phytoestrogen mangostin (10-5_10-8
M, 90% purity; a generous gift from L.A.
Sopasorya, Bandung, Indonesia). The struc-
ture of control substances and investigated
phytoestrogens is shown in Figure 1.
Cell culture. RUCA-I cells were precul-
tured for 2 days on plastic in Dulbecco's
modified Eagle's medium (DMEM)/F12
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medium containing 5% dextran-coated-
charcoal-stripped (DCC) serum. After har-
vesting, 300,000 RUCA-I cells were seeded
on top of 230 pl extracellular matrix
(Harbour Matrix, TEBU, Frankfurt,
Germany) per well of a 24-well dish and
cultured in the presence of2 ml ofa previ-
ously described serum-free defined medium
(SFDM) (15) for 80 hr, the first 24 hrwith-
out additional hormonal treatment.
Medium was changed daily, and hormonal
treatment was repeated. To investigate
potential estrogenic effects ofcompounds
released from plastic culture dishes, RUCA-I
cells were also cultured on top of an extra-
cellular matrixplated onglass culture dishes.
Hormonal treatment. Following 24 hr
culture on top of an extracellular matrix,
RUCA-I cells were treated with the estro-
genic and antiestrogenic substances
described above for 56 hr. Estrogenic and
antiestrogenic substances were added from
stock solutions in ethanol at a volume of
0.1% of total culture medium. Controls
received ethanol only.
Metabolic labeling ofsecretoryproteins.
After 24-48 hr of hormonal treatment,
secretory proteins were labeled metabolical-
ly with 35S-methionine (DuPont, Brussels,
Belgium). For this purpose cells were cul-
tured for another 16 hr in 150 1l medium
per well, whose methionine content was
reduced by 90% and substituted with
200 pCi/ml 35S-methionine. Thereafter
supernatants containing de novosynthesized
metabolically labeled secretory proteins
were collected and centrifuged (3 min at
3000g). We used 15 pl of the supernatant
to determine the incorporation rate of the
radioactive amino acid into trichloroacetic
acid-precipitable material; the remainder
was used for electrophoresis in 6% sodium
dodecylsulfate (SDS)-polyacrylamide gels.
Electrophoresis. Metabolically labeled
proteins were separated according to stan-
dard protocols using adiscontinuous system
(16), nonreducing conditions, and 6%
SDS-polyacrylamide gels. The same
amount ofradioactive counts ofeach exper-
imental condition was loaded per lane onto
thegel. Afterelectrophoresis, gelswere fixed
in 10% acetic acid, 30% methanol, incu-
bated in En3hance (DuPont), and dried for
1 hr at 80°C under vacuum. Bands were
visualized by autoradiography. For semi-
quantitative densitometric analysis, autora-
diographs were scanned with the JX-330
scanner and theJX-3F6 scanning unit. The
size and intensity of bands were anlyzed
with the Bio Image Intelligent Quantifier
(IQ) program, version 2.1, installed on a
Macintosh computer.
Ligand-bindingassy. Theligand-binding
affinity ofthe estrogenic and antiestrogenic
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Figure 1. Molecular structures of 17p-estradiol, the pure antagonist ICI 164384, and phytoestrogens
coumestrol, genistein, daidzein, andthe putative estrogen mangostin.
Table 1. Relative binding affinites of coumestrol, genistein, daidzein, and mangostin compared to 171-
estradiol
Evaluation method Coumestrol(%) Genistein(%) Daidzein(%) Mangostin(%)
y-Axis 2.15 ± 1 0.82 + 0.48 0.015± 0.011 0.00075 ± 0.00017
Slope 1.88 ± 0.84 0.92± 0.4 0.015 ± 0.01 0.00078 ± 0.00018
Binding affinities were evaluated byusingthe slope orthe intersection ofy-axis ofthe Scatchard analysis. Both evaluadon
methodsgave similiarresults.
substances described above was assessed bya
competitive Scatchard analysis as described
previously (17,18) using the cytosol of
RUCA-I cells. For this purpose RUCA-I
cells were cultured on plastic to near conflu-
ency in the presence ofDMEM/F12 medi-
um containing 5% DCC serum, then
trypsinized, pelleted by centrifugation
(800g, 4°C), and washed twice with phos-
phate-buffered saline. The pellet was resus-
pended in an extraction buffer (151) (0.01 M
Na2MoO4, 0.01 M NaH2PO4, 0.0015 M
Na-EDTA, 10% glycerin, 0.01 M monoth-
ioglycerol), and the cells were lysed by three
freeze-thaw cycles in liquid nitrogen. The
lysed cells were centrifuged for 45 min
(105,000g, 4°C) to yield the supernatant
(=cytosol). Total binding was assessed by
incubation of aliquots (100 1A) ofcytosol
with eight different concentrations of [3H]
E2 (Amersham, Braunschweig, Germany)
ranging from 0.05 to 1 nM for 18 hr at
4°C. To compare the binding affinity of
tested compounds to that ofestradiol 1-10
pM, unlabeled estradiol was additionally
added and used to generate a reference. For
comparative purposes the ideal concentra-
tion ofthe competitor (either estradiol as a
reference or phytoestrogens as test com-
pounds) should be titrated to a concentra-
tion that competes for 30-70% ofthe bind-
ingactivitymeasuredfor [3H]-E2alone. The
binding affinity ofthe unlabeled competi-
tors was determined as described above for
unlabeled estradiol except that coumestrol,
daidzein, genistein, or mangostin were used
at concentrations ranging from 10-5 to 10r9
M to compete for binding of [3H]-E2. For
the estimation of nonspecific binding, 200
nM ofunlabeled estradiol was added to the
incubation mixture. After incubation, free
steroids were absorbed from samples by
treatment with charcoal dextran for 10 min
at 40C. Specific bindingwas then calculated
from total binding minus nonspecific bind-
ingvalues.
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Figure 2. Relative binding affinities of the phytoestrogens (A) coumestrol, (B) genistein, (C) d
(D) mangostin evaluated by competitive binding assay according to Scatchard. Abbreviation
gen receptor; E2, 171-estradiol; cpm, counts per minute; Bs, specific bound; Bs/F, ratio ofsp'
tofree hormone.
Results
Binding affinity ofselectedphytoestrogens.
The relative binding affinity ofthe phytoe-
strogens coumestrol, genistein, daidzein,
and the putative phytoestrogen mangostin
to the ER was assessed by a competitive lig-
and-binding assay according to Scatchard
(17,18). Using the cytosolic preparation of
rat endometrial adenocarcinoma cells, the
following affinity ranking to the ER was
evaluated: E2 >>> coumestrol > genistein >
daidzein >>> mangostin..The binding
affinities ofthe phytoestrogehs compared to
E2 ranged from approximately 2% for
coumestrol to 0.00075% for mangostin
(Table 1). The evaluation ofbinding affini-
ties by either slopes of the linearized
Scatchard curves or their intersections with
y-axis lead to comparable results. In Figure
2 representative examples from competitive
Scatchard binding assays are shown. From
Scatchard analyses, general binding charac-
teristics ofthe ER, such as the maximum of
available binding sites and dissociation con-
stant, can be determined. The mean ER
content in RUCA-I cells originating from
passage 30 for these series of experiments
was calculated to be 65.5 ± 15.
cytosolic protein, and the high
demonstrated by the mean di
constant of estradiol to the ER
0.36 x 10-11 mol/l.
Effects ofphytoestrogens on
and secretion ofcomplement C3
positive RUCA-I cells respond tc
treatment ifcultured on a reconsti
ment membrane. In this cell culi
the formation ofcomplement C3
by E2 and is repressed by the pur
gen ICI 164384 (15). Changes
synthesis ofsecreted proteins afte.
withhormones, hormonelike subs
antihormones were assessed by
labeling focused on the analysis
ment C3. This protein is the majc
regulated secretory protein ofthe
uterus in vivo (20,21). The meta
ing experiments revealed that the
gens coumestrol, genistein, an
increased de novo synthesis ofsec
plement C3. Mangostin did not s
alter the formation ofcomplemen
3 and 4). In our model system
acts as an estradiol agonist at a co
of106 M, wherereas ICI 164384 is antago-
nistic and represses production ofcomple-
ment C3 even below control levels (Fig. 4).
Semiquantitative densitometric analysis (Fig.
4) revealed that the increase in production of
complement C3 protein byE2 (10O M) was
about twofold, and the induction at ahigher
concentration of E2 (10-7 M) was slightly
smaller. The phytoestrogens coumestrol,
genistein, and daidzein had to be adminis-
tered at an approximately 100 times higher
concentration compared to E2 to induce the
same estrogenic effect (Fig. 4). Additionally,
this study dearly showed that the degree of
400 5w induction of complement C3 production
mediated by phytoestrogens coumestrol,
genistein, and daidzein did not correlate to
the level that would have been predicted
from their relative bindingaffinityto the ER.
The three compounds had strikingly differ-
ent binding affinities to the ER (Table 1),
but all three (at a concentration of 106 M)
increased the formation ofcomplement C3
almost equally to about twofold. Providing
further evidence that induction of comple-
ment C3 by the phytoestrogens, as exampli-
fled by coumestrol, is nevertheless an ER-
mediated effect, increasing concentrations of
ICI 164384 were simultaneously added to
mw i. oo coumestrol-treated cells (Fig. 5). The admin-
istration ofICI 164384 resulted in a reduc-
tion of coumestrol-induced formation of
laidzein, and complement C3 in a dose-dependent man-
Is: ER, estro- ner. The highest concentration of ICI
ecific bound 164384 (5 x 10-7 M) resulted in a more
than twofold inhibition. Culture ofRUCA-I
cells on top ofextracellular matrix in glass
5 fmol/mg culture dishes resulted in a reduction ofcon-
affinity is trol levels of complement C3 (data not
tssociation shown), but this effect varied strongly
of 1.15 ± betweensingle experiments.
Regulation ofComplement C3 Steady-
formation state mRNA Level by Phytoestrogens. To
1. The ER- investigate the level ofregulation ofinduc-
) hormonal tion of complement C3, Northern blot
itutedbase- analyses were performed. As shown in
ture model Figure 6, the steady-state mRNA level of
is induced complement C3 is clearly increased by E2
*e antiestro- and by the phytoestrogens daidzein and
in de novo genistein. The putative phytoestrogen
r treatment mangostin leaves the level of complement
;tances, and C3 mRNA unchanged.
metabolic
ofcomple- Discussion
)restradiol- The rat endometrial adenocarcinoma cell
normal rat line RUCA-I represents a valuable model
ibolic label- system for the assessment of ER-mediated
phytoestro- estrogenic potency of environmental estro-
d daidzein gens. These cells contain a relatively high
-reted com- amount of ER (13) compared to other
ignificantly endometrial cell lines (22) and respond to E2
it C3 (Figs. treatment with increased proliferation and
tamoxifen increase ofestrogen-dependent complement
ncentration C3 production (14,15,23). RUCA-I cells
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Figure 3. Effects of estrogenic substances on de novo synthesis of complement C3. C, Control; E2, 17p-
estradiol; ICI, ICI 164384;Tam, tamoxifen; Gen, genistein; Dai, daidzein; Man, mangostin; Cou, coumestrol;
MWM, molecularweightmarker.
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Figure 4. Effects of phytoestrogens on production of complement C3. Semiquantative evaluation by den-
sitometry of autoradiographs. Abbreviations: E2, 17p-estradiol; ICI, ICI 164384; Tam, tamoxifen; Comp, test-
ed substance. Number of experiments: n = 3 for 103 M E2, n = 7 for 10-8 M E2, n = 8 for 5 x 101 M ICI
164384, n = 4for 5 x 108 M ICI 164384, n = 8 for tamoxifen, n = 3 for genistein except 105 M (n = 2), n = 2
for daidzein, and n = 3for mangostin except 10- M (n = 2). Error bars indicate standard deviations.
and regulation ofcomplement C3 expression
represent a sensitive model system to assess
-Rbronectin functions ofxenoestrogens in atissue-specific
endometrial-derived experimental model.
ComplementC3 Tissue-specific analysis is an important issue
that can most easily be exemplified with
tamoxifen. Jordan (24) has provided many
examples to experimentallyexplore the mole-
cular basis of the benefit of treating breast
cancer patients with the antiestrogen tamox-
*-- Fibronectin ifen (25). However, Jordan and co-workers
(26,27) also reported that endometrial ade-
nocarcinoma cells xenografted to athymic
-- ComplementC3 nude mice exhibit growth stimulation after
tamoxifen treatment. This situation, which is
also seen in patients, can be mimicked with
the RUCA-I-model. In xenotransplants of
RUCA-I cells to syngeneic DA-Han rats,
tamoxifen is a promotor of growth and
metastasis (23) and triggers increased tran-
scription ofestrogen-dependent genes (26).
Therefore, anotheradvantageofthe RUCA-I
e ComplementC3 system is that anyfinding in RUCA-I cells is
not only representative for rat endometrium
but maybeextrapolated to humans.
Each of the four tested phytoestrogens
boundwith distinct andconsiderablydiffer-
ent affinities to the ER. The relative bind-
ing affinities determined for coumestrol,
genistein, and daidzein are in the range of
data described in the literature (29,30),
which is important because the ER of
RUCA-I cells exhibit an unusually low KD
between 1 x 10-11 and 1 x 10-12 M. These
three phytoestrogens are able to increase the
formation of complement C3. The differ-
ence in binding affinity to the ER among
the phytoestrogens, which are capable of
inducing gene expression, is almost two
orders of magnitude and spans from
coumestrol, the phytoestrogen with the
highest binding affinity, to daidzein, the
phytoestrogen with the lowest binding
affinity. Despite different binding affinities,
genistein and daidzein at a concentration of
106 M, and coumestrol at a concentration
of 10-7 M increase formation of comple-
ment C3 more than 200%. Consequently,
the degree ofincrease ofprotein formation
is not strongly correlated with their binding
affinity to the ER. This means that investi-
gations using only binding affinity to assess
estrogenic potency of environmental estro-
gens canyield misleadingconclusions.
The apparent disagreement between the
binding affinity ofgenistein and daidzein,
which is around 50-fold, and the almost
equipotent induction ofmolecularendpoints
by these substances is surprising and might
be caused by serveral nonestrogenic features
of genistein. Genistein is known to be an
inhibitor of phosphotyrosine kinases (31)
and topoisomerases I and II (32. These two
features ofgenistein interfere severely with
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essential functions ofcells. The reduction of
phosphorylation by genistein can shut down
signal transduction cascades, resulting in
reduced proliferation. It is also known that
genistein inhibits the tyrosine-specific kinase
activity of the epidermal growth factor
(EGF) receptor in vitro(31), which in turn is
known to trigger ligand-independent activity
ofthe ER (33). The mechanism ofcross-talk
between EGF and ERhas not been elucidat-
edyet, but itis known that itis notmediated
byprotein kinase C orprotein kinaseA (34).
Genistein binds to the ER but potentially
interferes additionally with ligand-indepen-
dentestrogenicpathways.
Another cause for the lack ofcorrelation
between relative binding affinity and biolog-
ical potency on gene expression may be the
feature of some phytoestrogens to exhibit
antiestrogenic properties in addition to their
well-known agonistic effects (35). In our
assays we failed to inhibit the effect ofestra-
diol with phytoestrogens (data not shown).
However, ifwe use fibronectin as a marker
(Fig. 3), which in RUCA-I cells is an anti-
estrogen-induced protein (14), and therefore
represents antiestrogenicity, we find a rela-
tively strong induction by genistein and a
weak induction by daidzein. These diverg-
ing results are difficult to explain, but it has
been suggested that the effect of an exoge-
nous weak estrogen may act agonistically
and/or antagonistically depending on
endogenous steroid levels (36,34). Again the
situation in RUCA-I cells appears different,
as levels of complement C3 (agonistic
response) rise at the same time as those of
fibronectin (antagonistic response) after
genistein treatment. The regulatory features
of phytoestrogens on complement C3
expression resemble those ofsex hormone-
binding globulin production byendogenous
steroids (38) and isoflavonoids (39) in
HepG2 liver cells. In this system there is
also no correlation between relative binding
affinities and biological response. However,
there is also one majordissimiliarity between
the two systems. Complement C3 expres-
sion is clearly regulated by a transcriptional
mechanism, whereas the regulation of sex
hormone-binding globulin appears to be
post-transcriptionally regulated (3Sf).
Recent publications show that coume-
strol exhibits comparatively strong estrogenic
effects (40), such as increasing uterine wet
weight. On the other hand, coumestrol can
cause hypermethylation of the H-ras proto-
oncogene, whereas no change in methylation
was observed in the proto-oncogene c-mycor
c-fos (41). Methylation is thought to be
involved in the activation (hypomethylation)
and inactivation (hypermethylation) of pro-
moter activity of cellular genes. Coming
back to the issue of tumor prevention by
U Fibronectin
- Complement C3
C E2 ICI Coul104M CoulO4M Cou 104M Cou 10-6M MWM
104M 5x 107M + ICI +ICI +ICI
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Figure 5. (A) Effects of estrogenic sub-
stances on de novo synthesis of secreted
400 complement C3. Labeled proteins were
separated on a 6% sodium dodecyl sul-
1 300 = @ fate-polyacrylamide gel. Abbreviations: C,
S control; E2, 17J-estradiol; ICI, ICI 164384;
2W _ - Cou, coumestrol; MWM, molecularweight
marker. (B) Semiquantative densitometric
100 analysis of induction of complement C3 by
coumestrol and competitive inhibition by
ICI 164384.
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phytoestrogens, it is likely that phytoestro-
gens use different mechanisms to develop
their cancer protective effects. Additionally,
undiscovered properties of phytoestrogens
such as tissue specificity might be responsi-
ble for other beneficial effects on human
health regarding cardiovascular diseases or
Alzheimer's disease.
In this study we were able to show that
the extent of induction of molecular end-
points by the phytoestrogens coumestrol,
genistein, and daidzein is not strongly cor-
related to the extent oftheir binding affini-
ty to the ER. Furthermore, it could be
proved that the regulation of increase of
complement C3 is mediated by an increase
of its mRNA level. The RUCA-I cell line
represents a valuable endometrial-derived
model to identify molecular mechanisms
mediated byphytoestrogens.
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